NCT00343421View on ClinicalTrials.gov

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

588

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2009

Conditions
DiphtheriaTetanusPertussisPoliomyelitisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

PEDIACEL® and Prevenar®

0.5 mL each, IM (opposite thigh)

BIOLOGICAL

Infanrix®-IPV+Hib and Prevenar®

0.5 mL each, IM (opposite thigh)

Trial Locations (2)

Unknown

Paris

Poznan

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00343421 - Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers | Biotech Hunter | Biotech Hunter